Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10374897" target="_blank" >RIV/00216208:11150/18:10374897 - isvavai.cz</a>

Výsledek na webu

<a href="https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-018-0271-1" target="_blank" >https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-018-0271-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12986-018-0271-1" target="_blank" >10.1186/s12986-018-0271-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements

Popis výsledku v původním jazyce

Branched-chain amino acids (BCAAs; valine, leucine, and isoleucine) are essential amino acids with protein anabolic properties, which have been studied in a number of muscle wasting disorders for more than 50 years. However, until today, there is no consensus regarding their therapeutic effectiveness. The aims of the article are: (i) to review the main metabolic pathways and supposed effects of the BCAA, (ii) explain the causes of altered metabolism and BCAA levels in various healthy and pathological conditions, and (iii) provide current views on their use as supplements for the possible main indications. The crucial role in BCAA metabolism play: (i) skeletal muscle as the initial site of BCAA catabolism accompanied with the release of alanine and glutamine to the blood; (ii) activity of branched-chain keto acid dehydrogenase (BCKD); and (iii) amination of branched-chain keto acids (BCKAs) to BCAAs. Enhanced consumption of BCAA for ammonia detoxification to glutamine in muscles is the cause of decreased BCAA levels in liver cirrhosis and urea cycle disorders. Increased BCKD activity is responsible for enhanced oxidation of BCAA in chronic renal failure, trauma, burn, sepsis, cancer, phenylbutyrate-treated subjects, and during exercise. Decreased BCKD activity is the main cause of increased BCAA levels and BCKAs in maple syrup urine disease, and plays a role in increased BCAA levels in diabetes type 2 and obesity. Increased BCAA concentrations during brief starvation and type 1 diabetes are explained by amination of BCKAs in visceral tissues and decreased uptake of BCAA by muscles. The studies indicate beneficial effects of BCAAs and BCKAs in therapy of chronic renal failure and a need of therapeutic strategies to avoid adverse effects of the BCAA administration on ammonia production in cirrhosis. Further studies are needed to elucidate the effects of BCAA supplementation in burn, trauma, sepsis, cancer and exercise. Whether increased BCAA levels are beneficial or harmful and whether contribute to insulin resistance should be known before the decision regarding their suitability in obese subjects and patients with type 2 diabetes. It is concluded that alterations in BCAA metabolism have been found common in a number of disease states, and careful studies are needed to elucidate their therapeutic effectiveness in most indications.

Název v anglickém jazyce

Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements

Popis výsledku anglicky

Branched-chain amino acids (BCAAs; valine, leucine, and isoleucine) are essential amino acids with protein anabolic properties, which have been studied in a number of muscle wasting disorders for more than 50 years. However, until today, there is no consensus regarding their therapeutic effectiveness. The aims of the article are: (i) to review the main metabolic pathways and supposed effects of the BCAA, (ii) explain the causes of altered metabolism and BCAA levels in various healthy and pathological conditions, and (iii) provide current views on their use as supplements for the possible main indications. The crucial role in BCAA metabolism play: (i) skeletal muscle as the initial site of BCAA catabolism accompanied with the release of alanine and glutamine to the blood; (ii) activity of branched-chain keto acid dehydrogenase (BCKD); and (iii) amination of branched-chain keto acids (BCKAs) to BCAAs. Enhanced consumption of BCAA for ammonia detoxification to glutamine in muscles is the cause of decreased BCAA levels in liver cirrhosis and urea cycle disorders. Increased BCKD activity is responsible for enhanced oxidation of BCAA in chronic renal failure, trauma, burn, sepsis, cancer, phenylbutyrate-treated subjects, and during exercise. Decreased BCKD activity is the main cause of increased BCAA levels and BCKAs in maple syrup urine disease, and plays a role in increased BCAA levels in diabetes type 2 and obesity. Increased BCAA concentrations during brief starvation and type 1 diabetes are explained by amination of BCKAs in visceral tissues and decreased uptake of BCAA by muscles. The studies indicate beneficial effects of BCAAs and BCKAs in therapy of chronic renal failure and a need of therapeutic strategies to avoid adverse effects of the BCAA administration on ammonia production in cirrhosis. Further studies are needed to elucidate the effects of BCAA supplementation in burn, trauma, sepsis, cancer and exercise. Whether increased BCAA levels are beneficial or harmful and whether contribute to insulin resistance should be known before the decision regarding their suitability in obese subjects and patients with type 2 diabetes. It is concluded that alterations in BCAA metabolism have been found common in a number of disease states, and careful studies are needed to elucidate their therapeutic effectiveness in most indications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nutrition &amp; Metabolism

ISSN

1743-7075

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

33

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

000431530300001

EID výsledku v databázi Scopus

2-s2.0-85046552521